[BLUE] bluebird bio, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 64.65 Change: 2.15 (3.44%)
Ext. hours: Change: 0 (0%)

chart BLUE

Refresh chart

Strongest Trends Summary For BLUE

BLUE is in the medium-term down -36% below S&P in 1 year and down -48% below S&P in 1 year. In the long-term down -64% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company?s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS-7.22 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0.14% Sales Growth - Q/Q-0.66% P/E-15.06
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-11.78% ROE-13.25% ROI
Current Ratio8.11 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin-294.47% Net Profit Margin-247.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.46 M Cash From Investing Activities-192.98 M Cash From Operating Activities-24.16 M Gross Profit
Net Profit-24.79 M Operating Profit-24.93 M Total Assets533.82 M Total Current Assets340.84 M
Total Current Liabilities42.01 M Total Debt Total Liabilities59.32 M Total Revenue6.34 M
Technical Data
High 52 week162.45 Low 52 week85.49 Last close89.55 Last change0.87%
RSI22.21 Average true range4.12 Beta1.73 Volume513.89 K
Simple moving average 20 days-5.15% Simple moving average 50 days-13.63% Simple moving average 200 days-29.27%
Performance Data
Performance Week0.95% Performance Month-16.2% Performance Quart-35.78% Performance Half-41.86%
Performance Year-28.98% Performance Year-to-date-9.73% Volatility daily2.57% Volatility weekly5.75%
Volatility monthly11.78% Volatility yearly40.8% Relative Volume135.56% Average Volume645.24 K
New High New Low

News

2020-06-04 16:01:36 | Pliant Therapeutics Shares Have Climbed 44% Since This Week's IPO

2020-06-03 16:05:00 | bluebird bio Announces That Its 2020 Annual Meeting of Stockholders Will Be Held in Virtual Format

2020-05-28 08:00:00 | bluebird bio Announces Live Webcast of EHA Data Review and June Investor Events

2020-05-27 10:35:00 | What Sanofi Might Buy With Its Regeneron Windfall

2020-05-25 12:00:04 | Bluebird BLUE Upgraded to Buy: What Does It Mean for the Stock?

2020-05-22 11:10:33 | FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”

2020-05-19 18:53:20 | 8 Biotechs Tapping Secondary Markets for $3 Billion

2020-05-19 07:19:24 | Bluebird Prices New Shares At $55, Seeks To Raise $500 Million

2020-05-18 21:32:00 | bluebird bio Announces Pricing of Public Offering of Common Stock

2020-05-18 07:08:00 | Bluebird Bio's stock falls after proposed public stock offering

2020-05-18 07:08:00 | Bluebird Bio's stock falls after proposed public stock offering

2020-05-18 07:00:00 | bluebird bio Announces Proposed Public Offering of Common Stock

2020-05-15 09:01:01 | bluebird BLUE: Strong Industry, Solid Earnings Estimate Revisions

2020-05-14 09:00:00 | bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual Congress

2020-05-13 17:00:00 | Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20

2020-05-13 10:41:00 | Bristol-Myers, Bluebird Bio to Resubmit FDA Bid for Myeloma Treatment

2020-05-13 09:54:00 | Better Buy: bluebird bio vs. Exelixis

2020-05-13 07:45:00 | Bluebird, Bristol-Myers Squibb have resubmit FDA bid for CAR-T therapy

2020-05-13 06:59:00 | Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel ide-cel, bb2121 for the Treatment of Patients with Multiple Myeloma

2020-05-12 13:40:00 | Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering

2020-05-11 12:01:00 | Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout

2020-05-11 11:22:13 | Bristol Myers to pay bluebird $200 million for future royalties on cancer therapies

2020-05-11 08:25:12 | Bluebird Bio BLUE Reports Q1 Loss, Tops Revenue Estimates

2020-05-11 07:35:00 | bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement

2020-05-11 07:00:00 | bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results

2020-05-08 09:55:01 | Is a Surprise Coming for bluebird bio BLUE This Earnings Season?

2020-05-08 07:30:00 | bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program

2020-04-30 06:27:00 | Better Buy: Crispr Therapeutics vs. bluebird bio

2020-04-29 08:00:00 | bluebird bio Announces First Quarter 2020 Earnings Conference Call and May Investor Event

2020-04-28 12:44:00 | How These 15 Stock Suggestions Fared Against the Market

2020-04-20 08:51:12 | bluebird bio BLUE Catches Eye: Stock Jumps 6%

2020-04-05 21:02:23 | Is bluebird bio Inc BLUE A Good Stock To Buy?

2020-04-03 18:34:00 | 7 Biotech Stocks to Buy for a Post-Pandemic World

2020-03-31 06:59:00 | Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application BLA for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel Ide-cel, bb2121 to FDA

2020-03-31 06:51:10 | What You Need To Know About The bluebird bio, Inc. NASDAQ:BLUE Analyst Downgrade Today

2020-03-30 11:35:58 | Cell and gene therapy firm raises $170M investment

2020-03-26 12:36:19 | Biotech delays U.S. gene therapy launch due to outbreak, FDA discord

2020-03-26 07:30:00 | bluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Development

2020-03-19 11:30:03 | Bluebird BLUE Down 47.8% Since Last Earnings Report: Can It Rebound?

2020-02-20 06:31:54 | bluebird bio, Inc. Just Released Its Annual Results And Analysts Are Updating Their Estimates

2020-02-19 07:59:32 | Blood disorder startup files for $86M IPO

2020-02-18 16:05:00 | bluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progress

2020-02-17 06:17:17 | Some bluebird bio NASDAQ:BLUE Shareholders Are Down 35%

2020-02-13 12:31:05 | Analysts Estimate Bluebird Bio BLUE to Report a Decline in Earnings: What to Look Out for

2020-02-05 08:00:00 | bluebird bio Announces Upcoming Investor Events

2020-02-04 11:28:18 | Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter

2020-01-28 05:26:18 | Acceleron stock soars on lung drug trial data

2020-01-13 05:00:00 | bluebird bio Announces Launch in Germany of ZYNTEGLO™ autologous CD34+ cells encoding ?A-T87Q-globin gene Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent ?-Thalassemia Who Do Not Have ?0/?0 Genotype

2020-01-08 17:50:10 | Bluebird Bio BLUE Outpaces Stock Market Gains: What You Should Know

2020-01-03 14:44:42 | 3 Beaten-Up Biotech Stocks That Just Got More Enticing